Long-term efficacy and safety of inebilizumab in neuromyelitis optica spectrum disorder: Analysis of aquaporin-4-immunoglobulin G-seropositive participants taking inebilizumab for â©¾4 years in the N-MOmentum trial.

Rensel, Mary; Zabeti, Aram; Mealy, Maureen A; Cimbora, Daniel; She, Dewei; Drappa, Jorn; Katz, Eliezer

Rensel, Mary; Zabeti, Aram; Mealy, Maureen A; Cimbora, Daniel; She, Dewei; Drappa, Jorn; Katz, Eliezer.

Afiliação

Rensel M; Mellen Center for Multiple Sclerosis, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA.
Zabeti A; Mellen Center for Multiple Sclerosis, Cleveland Clinic, Cleveland, OH, USA.
Mealy MA; University of Cincinnati, Cincinnati, OH, USA.
Cimbora D; Horizon Therapeutics plc, Deerfield, IL, USA; (known as Viela Bio at the time of study conduct).
She D; Horizon Therapeutics plc, Deerfield, IL, USA; (known as Viela Bio at the time of study conduct).
Drappa J; Horizon Therapeutics plc, Deerfield, IL, USA; (known as Viela Bio at the time of study conduct).
Katz E; Horizon Therapeutics plc, Deerfield, IL, USA; (known as Viela Bio at the time of study conduct).

Mult Scler ; 28(6): 925-932, 2022 05.

Article em En | MEDLINE | ID: mdl-34595983

Assuntos

Anticorpos Monoclonais Humanizados; Neuromielite Óptica; Adulto; Anticorpos Monoclonais Humanizados/efeitos adversos; Aquaporina 4; Autoanticorpos; Humanos; Imunoglobulina G/uso terapêutico; Neuromielite Óptica/tratamento farmacológico

Palavras-chave

Anti-CD19 monoclonal antibody; neuromyelitis optica spectrum disorder; optic neuritis; transverse myelitis

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neuromielite Óptica / Anticorpos Monoclonais Humanizados Tipo de estudo: Clinical_trials Limite: Adult / Humans Idioma: En Revista: Mult Scler Assunto da revista: NEUROLOGIA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google